Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 87.81M | 85.53M | 86.55M | 87.37M | 88.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.81M | 85.53M | 86.55M | 87.37M | 88.75M |
| Cost of Revenue | 36.74M | 35.56M | 36.64M | 37.58M | 38.21M |
| Gross Profit | 51.07M | 49.97M | 49.91M | 49.79M | 50.54M |
| SG&A Expenses | 36.66M | 35.44M | 35.56M | 37.76M | 39.53M |
| Depreciation & Amortization | 3.35M | 3.69M | 4.03M | 4.43M | 4.91M |
| Other Operating Expenses | -- | -- | 171.00K | 171.00K | 171.00K |
| Total Operating Expenses | 85.84M | 83.52M | 85.22M | 88.91M | 92.23M |
| Operating Income | 1.97M | 2.01M | 1.33M | -1.54M | -3.48M |
| Income Before Tax | -10.54M | -9.90M | -57.39M | -53.59M | -56.95M |
| Income Tax Expenses | -129.00K | -115.00K | -686.00K | 243.00K | 457.00K |
| Earnings from Continuing Operations | -10.41 | -9.78 | -56.70 | -53.84 | -57.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.41M | -9.78M | -56.70M | -53.84M | -57.41M |
| EBIT | 1.97M | 2.01M | 1.33M | -1.54M | -3.48M |
| EBITDA | 7.37M | 7.65M | 7.27M | 4.82M | 3.37M |
| EPS Basic | -2.32 | -2.20 | -12.84 | -12.20 | -13.03 |
| Normalized Basic EPS | -1.36 | -1.29 | -1.25 | -0.71 | -1.18 |
| EPS Diluted | -2.35 | -2.23 | -12.88 | -12.24 | -13.04 |
| Normalized Diluted EPS | -1.36 | -1.29 | -1.25 | -0.71 | -1.18 |
| Average Basic Shares Outstanding | 17.91M | 17.82M | 17.76M | 17.66M | 17.57M |
| Average Diluted Shares Outstanding | 17.91M | 17.82M | 17.76M | 17.74M | 17.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |